2022/23 NHS priorities and operational planning guidance in England

03

May 2022

On April 12, 2022, NHS England and NHS Improvement (NHSE/I) published 2022/23 priorities and operational planning guidance, with three supporting documents:

  • Elective recovery planning supporting guidance;
  • Capital guidance for 2022-25;
  • Revenue finance and contracting guidance.

Elective recovery plan key objectives include the following: expand capacity to reduce waiting times, prioritize treatment based on clinical urgency, move the location of elective care services to drive productivity (e.g., through community diagnostic centers, surgical hubs, and improved patient pathways).

Several ambitions are defined, including reducing waiting times for diagnostic tests (95% of patients receive them within six weeks) and cancer diagnosis (75% of patients referred for suspected cancer are diagnosed or have cancer ruled out within 28 days).

The following funding is available for elective recovery over 2022/23:

  • £1.5 billion of capital above that funded within core envelopes has been made available to the NHS over three years to support new surgical hubs, increased bed capacity, and equipment to help elective services recover;
  • £2.3 billion to transform diagnostic services, including at least 100 community diagnostic centers across England, to permanently increase diagnostic capacity.

Capital guidance defines the scope of capital envelopes for three years (2022 to 2025). The scope was updated to include primary care capital and indicative funding allocations for diagnostic, digital, and elective recovery capital. The system operational capital envelopes for 2022/23 will include the replacement of diagnostic (e.g., CT and MRI machines) and radiotherapy equipment.

For 2022/23, the NHS capital allocation will be split into three categories:

  • A system-level allocation (£4.1 billion) to cover day-to-day operational investments, which have typically been self-financed by organizations in integrated care systems (ICS) or financed by the Department of Health and Social Care (DHSC). From 2022/23 onwards, this includes a £0.1 billion investment in primary care estates and IT. In 2021/22, this was £3.9 billion (excluding primary care);
  • Nationally allocated funds (£1.1 billion) to cover nationally strategic projects already announced and in development or construction, such as hospital upgrades and new hospitals. In 2021/22, this was £1.2 billion;
  • Other national capital investment (£2.7 billion), including national programs such as elective recovery, diagnostics, and national technology funding. In 2021/22, this was £1.7 billion.

According to revenue finance and contracting guidance, from 2022/23, all national High Cost Tariff Excluded Devices (HCTED) funding will be managed on a national basis, outside baseline contracts between commissioners and providers. The national finance team will manage the monthly transactional process and reimburse trusts directly.

Revenue finance and contracting guidance also provide details on technology funding. ICSs will need to agree on how technology funding is to be allocated between their partners. However, the existing funding flows and mechanisms will remain - capital funding will flow from the DHSC to trusts, and revenue funding will flow to ICBs, which will then be able to pass it to trusts and other organizations.

See the full details on elective recovery planning supporting guidance here, capital guidance for 2022-25 here, and revenue finance and contracting guidance here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

20

May 2022

In April 2022, NHS England and NHS Improvement (NHSEI) announced that the timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23 are currently under review. Previously, NHSEI planned to publish and implement the 2022/23 Test Directory by April 2022. While the timelines are not confirmed, applications can still be submitted.

Read more

19

May 2022

On April 25, 2022, the Decision Forum for "New Method" did not prioritize any surgical procedure in the treatment of morbid obesity. Available evidence in the complete method assessment shows minor or no difference in weight loss, diabetes control, or health-related quality of life when using various surgical procedures. The comparative effect on the risk of early mortality, progression of obesity, and obesity-related comorbidities was not possible to determine. The cost differences are non-significant. Further research was recommended.

Read more

17

May 2022

On April 21, 2022, NHS England and NHS Improvement updated the 2021/22 National Genomic Test Directory (version 3), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Forty-two new codes (test-indication combinations) were introduced in the cancer field, and fourteen for rare and inherited diseases.

Read more

13

May 2022

In April 2022, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 0183 and 0080 with changes to be implemented no later than June 14, 2022. Eleven new procedure codes and nine new diagnostic codes were introduced.

Read more

10

May 2022

A new test called Genedrive System to detect babies at risk of gentamycin-related deafness was developed at the University of Manchester, funded by the National Institute for Health and Care Research (NIHR). On April 02, 2022, NHS England and NHS Improvement announced that Genedrive is now fully CE certified to be used in a clinical setting. The test is expected to be implemented in routine care in all NHS Manchester Foundation Trust hospitals within several weeks.

Read more